Key result
Long-term double filtration plasmapheresis reduced the annual rate of hypertriglyceridemia-associated pancreatic or cardiovascular complications from a median of 1.4 to 0.
Why the study?
Data on the long-term use of double filtration plasmapheresis to prevent severe hypertriglyceridemia-associated complications were scarce.
Does regular double filtration plasmapheresis reduce the incidence of pancreatic or cardiovascular complications in patients with severe refractory hypertriglyceridemia?
Observational (n=10)
Yes
Does regular double filtration plasmapheresis reduce the incidence of pancreatic or cardiovascular complications in patients with severe refractory hypertriglyceridemia?
Long-term regular double filtration plasmapheresis significantly reduces the recurrence of acute pancreatitis and progression of ASCVD in patients with severe, refractory hypertriglyceridemia.
Answers are grounded in this paper and cite their sources.
Long-term DFPP was associated with fewer HTG complications in refractory patients; leaves open need for prospective trials before practice change.
BACKGROUND: Severe hypertriglyceridemia (HTG) is associated with major complications such as acute or relapsing pancreatitis (AP) and atherosclerotic cardiovascular disease (ASCVD). Rapid elimination of triglyceride (TG)-rich lipoproteins (LP) with double filtration plasmapheresis (DFPP) without need for substitution has been found to be effective for the acute, short-term treatment of HTG-induced AP. Data on the long-term use of DFPP to prevent HTG-associated complications are scarce. OBJECTIVES: To evaluate the use and efficacy of regular DFPP treatment in clinical practice for preventing recurrence of HTG-associated complications in thera-py refractory patients. METHODS: Retrospective multicenter study in patients with severe symptomatic drug and diet refractory HTG with regular DFPP treatment. Patients' incidence of HTG-associated pancreatic or cardiovascular complications was compared before treatment and with regular DFPP treatment. RESULTS: Ten patients (3 female) were identified with baseline maximal TG concentrations of 2,587-28,090 mg/dL (median 5,487 mg/dL; interquartile range [IQR] 4,340-12,636). The mean observation period was 3.9 ± 3.4 years before and 3.8 ± 3.0 years after commencement of DFPP. In 5 patients, severe HTG was related to chylomicronemia, 2 patients had familial partial lipodystrophy Dunnigan, and 1 patient had additional LP(a)-hyperlipoproteinemia. The main HTG-associated complication was recurrent AP in 8 patients, including 1 patient treated during pregnancy. Two patients presented severe progressive ASCVD. With long-term DFPP treatment, the annual rate of HTG-associa-ted pancreatic or cardiovascular complications declined from median 1.4 (IQR 0.7-2.6) to 0 (IQR 0.0-0.4; p < 0.005). The absolute number of events was reduced by 77%. In 6 patients (60%) episodes of AP did not occur, nor was progression of ASCVD detected clinically or by routine imaging techniques. DFPP was effective in the elimination of TG-rich LP from plasma, and was safe and well-tolerated. CONCLUSION: Long-term, regular DFPP treatment resulted in stabilization of patients with severe HTG and related recurrent AP or progression of ASCVD, who were refractory to conventional dietary and drug therapy.
No takes yet. Share an insight, caveat, or question.
Grupp et al. (2020) conducted an observational in Severe hypertriglyceridemia (n=10). Double filtration plasmapheresis (DFPP) vs. Before treatment was evaluated on Annual rate of HTG-associated pancreatic or cardiovascular complications (p=<0.005). Long-term double filtration plasmapheresis reduced the annual rate of hypertriglyceridemia-associated pancreatic or cardiovascular complications from a median of 1.4 to 0.
Synapse has enriched 10 related papers. Consider them for comparative context: